eligibility_summary
Inclusion: Men ≥18 with bone mCRPC (PCWG3 progression), prior ≥1 chemo and ≥1 AR agent, zoledronic acid before lymphodepletion (switch from denosumab, ≥2 doses if naïve, resume ≥wk8), no anticancer tx ≤3 wks, Radium‑223/Puvicto ≤3 mo, or checkpoint ≤6 mo, ECOG ≤2/KPS ≥70, adequate organ/marrow, life ≥6 mo, contraception if fathering potential. Exclusion: active HBV/HCV/HIV, ONJ/ZA contraindication, major cardiac disease, active autoimmune (except stable thyroid), leptomeningeal/brainstem disease or untreated brain mets, seizure hx, active second cancer, uncontrolled illness/infection ≤28 d, prior pancreatitis, any condition deemed unsafe.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions and mechanisms: MSGV1-PSCA-8T28Z, an autologous gamma delta CAR T-cell therapy engineered to recognize Prostate Stem Cell Antigen (PSCA), redirecting γδ T-cell activation and cytotoxicity against PSCA+ tumor cells. Fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylating agent) are given for lymphodepletion to reduce host lymphocytes/regulatory cells and enhance CAR T expansion/engraftment. Targets: PSCA on metastatic castration‑resistant prostate cancer cells, immune pathways engaged include CAR-mediated T-cell activation and cytolytic effector functions of γδ T cells.